Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy

(2010) Adi F. Gazdar   CANCER AND METASTASIS REVIEWS

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study

(2009) Ivette F Emery et al.   BMC CANCER

Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer

(2009) Hua Bai et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer

(2009) Shinobu Hosokawa et al.   LUNG CANCER

Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer

(2009) Seok Jin Kim et al.   MEDICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Network Branching in Eliciting Differential Short-Term Signaling Responses in the Hypersensitive Epidermal Growth Factor Receptor Mutants Implicated in Lung Cancer

(2008) J. Purvis et al.   BIOTECHNOLOGY PROGRESS

Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma

(2008) Naoki Hijiya et al.   HUMAN PATHOLOGY

Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling

(2008) Sebastian Zimmer et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation

(2008) Hideki Endoh et al.   LUNG CANCER